Navigation Links
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Date:4/4/2008

out limitation:

-- conducting the Company's Phase 2 High Dose Study for Zerenex;

-- continuing work on novel formulations of Zerenex and market research

for Zerenex;

-- terminating approximately 12 of 20 early-stage clinical studies of

KRX-0401 (perifosine);

-- delaying the commencement of a KRX-0401 (perifosine) Phase 3 trial

until additional data are accumulated and analyses are completed from

on-going exploratory studies of perifosine as a treatment for the

following tumor types: renal cell, colon, hepatocellular, multiple

myeloma, waldenstrom's macroglobulinemia and sarcoma;

-- terminating our license agreement for KRX-0601 (UCN-01); and

-- closing the Company's San Francisco, California and Memphis, Tennessee

offices and the Company's Wisconsin manufacturing suite which was

built to support the commercialization of Sulonex, and divesting the

assets from these facilities.

In addition, the Company will explore opportunities to monetize portions of the Company's technology assets, which may include partnerships, strategic alliances and pursuit of creative product-specific financing alternatives.

As a result of this restructuring, the Company will incur between $12 million and $15 million of charges in the first quarter of 2008, primarily associated with employee severance benefits and a non-cash write-off of the assets of the Company's Sulonex manufacturing facility.

As part of the workforce reduction, the position of President of the Company was eliminated and, accordingly, as previously reported, Dr. Craig Henderson, will be leaving the Company, effective as of April 15, 2008.

The Company believes that after the restructuring is completed, it will have the financial resources required to pursue its priority programs and that the remaining staff possess the core competencies necessary to effec
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
2. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals Announces Additions to Management Team
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 With bed bugs' presence ... that although bed bugs need to be eliminated, one must ... compromise a person's health. And so to help bed bug ... get rid of bed bugs without using harmful ... bug spray it called Bed Bug Bully. , According to ...
(Date:5/20/2013)... PA (PRWEB) May 20, 2013 Interventional ... Allegheny General Hospital (AGH) Cardiovascular Institute have ... coronary artery disease (CAD) over the past ... such as balloon angioplasty and coronary artery stent implantation. ... once again play a prominent role in the study ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 In Early ... the field of biotoxin related illnesses , announced his ... country able to advance his protocol for treating Chronic ... became the third physician to achieve certification in the ... Physicians, able to practice the Shoemaker Protocol in other ...
(Date:5/17/2013)... GA (PRWEB) May 17, 2013 Dr. ... Gynecology, and Women’s Health at the Albert Einstein College ... Oncology at the Montefiore Medical Center. He is ... Cancer Center and leads the Einstein Breast Cancer Working ... on translational breast cancer research. He also serves as ...
Breaking Biology Technology:New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... BOTHELL, WA and VANCOUVER, May 11 /PRNewswire-FirstCall/ - ... announced today that final survival data from a ... with docetaxel versus docetaxel alone as first-line chemotherapy ... be featured in an oral presentation at the ...
... manufacturer, Sepha Ltd, enters strategic European alliances and gears up for ... , ... Belfast (Vocus) May 11, 2009 -- The ... de-blistering equipment, Sepha Ltd is boosting its European distribution ...
... attempt to dismiss Bavarian Nordic,s patent infringement suit in ... Biomedica,made yet another attempt to dismiss the suit arguing ... clinical trials. The court ruled,against Oxford Biomedica and the ... patents. , Bavarian Nordic owns ...
Cached Biology Technology:OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 2OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 3Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 2Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 3The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:5/17/2013)... State University of New Jersey, and City University of ... Visikol TM that effectively clears organisms to be ... of chloral hydrate, which is one of the few ... regulated by the Drug Enforcement Administration (DEA) due to ... clearing agents, are vital for viewing organisms under a ...
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
(Date:5/17/2013)... project (Intelligent Cargo in Efficient and Sustainable Global Logistics ... an improvement in the efficiency of intermodal loading systems ... making. It comprises 29 European organisations with experience in ... has a budget totalling 17,000,000 and a duration of ... to specify and develop the semantic components and ontologies ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3SUMO wrestling cells reveal new protective mechanism target for stroke 2New logistics services that will cut energy consumption and CO2 emissions 2
... Leading bioscience funding bodies in the UK and USA ... transformational area of enhanced photosynthesis. The Biotechnology and ... Science Foundation (NSF) announce plans to hold an intensive ... in California later this year, to bring together leading ...
... of Cedars-Sinai Medical Center in Los Angeles, was presented ... annual Lifetime Achievement Award at its 2010 Annual Meeting. ... of contributions to genetic medicine, for his research into ... for helping to organize the field of medical genetics ...
... new tool to help marine biologists better grasp the processes ... unveil the bacterial community dynamics behind afflictions that bleach and ... March 30, 2010.) Warming waters are triggering coral ... Barrier Reef off the Australian coast. Now new mathematical models ...
Cached Biology News:BBSRC and NSF join together to promote new ideas to enhance photosynthesis 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 3New mathematical model helps biologists understand how coral dies in warming waters 2
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
... Heat activated ,• Eliminates nonspecific ... ,• Excellent specificity allows extension through ... structures ,• Leaves an 'A' overhang ... form of GeneChoice DNA Polymerase that ...
... aqueous solution. Cleaves a-(1-3)- ... carbohydrates and glycoproteins. It is particularly efficient ... the pH must be neutral or above, ... Unit Definition: One unit will ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: